Sevoflurane Concentration for Immobility

• Status: Completed
• Trial end date: 2021-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Sevoflurane is as attractive inhalation agent fore deep sedation in children undergoing short invasive procedure because of lack of irritation to the respiratory tract, a pleasant odor and rapid clinical effect and recovery due to low blood gas partition coefficient.

The aim of this study is to determine the optimum inspired concentration of sevoflurane required for immobility during botulinum toxin injection in spontaneously breathing children with cerebral palsy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yeungnam University College of Medicine
• Treatments: Botulinum Toxins; Sevoflurane

Criteria

Inclusion Criteria:

• 3-12 years old children with cerebral palsy receiving sevoflurane inhalation for botulinum toxin injection

• American society of anesthesiologists Physical status 1-2

Exclusion Criteria:

• Body mass index > 30 kg/m2

• unstable heart disease

• Anticipated difficult airway history including congenital facial or airway anomaly

• Recent upper respiratory tract infection ( < 2 weeks)

• Gastroesophageal reflux

• Allergy history to sevoflurane, remifentanil or any drug used during procedure